Novo Nordisk (NVO) Rises Higher Than Market: Key Facts

Novo Nordisk (NVO) closed at $36.98 in the latest trading session, marking a +1.37% move from the prior day. This move outpaced the S&P 500's daily gain of 0.11%. Elsewhere, the Dow saw a downswing of 0.13%, while the tech-heavy Nasdaq appreciated by 0.18%. Shares of the drugmaker witnessed a loss of 5.25% over the previous month, beating the performance of the Medical sector with its loss of 6.43%, and underperforming the S&P 500's loss of 4.28%.The upcoming earnings release of Novo Nordisk will be of great interest to investors. In that report, analysts expect Novo Nordisk to post earnings of $0.87 per share. This would mark a year-over-year decline of 5.43%. Simultaneously, our latest consensus estimate expects the revenue to be $11.06 billion, showing a 0.48% escalation compared to the year-ago quarter. For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $45.1 billion, signifying shifts of -15.15% and -3.59%, respectively, from the last year. Investors should also pay attention to any latest changes in analyst estimates for Novo Nordisk. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.04% lower. Currently, Novo Nordisk is carrying a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that Novo Nordisk has a Forward P/E ratio of 10.87 right now. This signifies a discount in comparison to the average Forward P/E of 14.79 for its industry. We can additionally observe that NVO currently boasts a PEG ratio of 8.63. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.36 as trading concluded yesterday. The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 158, positioning it in the bottom 36% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.SeeThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks